Pyxis Oncology, Inc. (PYXS) — Financial statements
Income statement, balance sheet, and cash flow for Pyxis Oncology, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 14↓14.2% | 16 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 2↑402.7% | 0.48 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 11↓26.8% | 16 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 74↑25.4% | 59↑18.5% | 50↓42.4% | 86↑68.7% | 51 | |
| General & Administrative Expenses | 22↓12.7% | 25↓22.0% | 33↓12.7% | 37↑100.1% | 19 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 22↓12.7% | 25↓22.0% | 33↓12.7% | 37↑100.1% | 19 | |
| Other Expenses | 0.00↓100.0% | 21 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 96↓8.8% | 105↑27.9% | 82↓33.4% | 123↑77.1% | 70 | |
| Total Costs & Expenses | 98↓6.9% | 106↑28.5% | 82↓33.4% | 123↑77.1% | 70 | |
| Operating Results | ||||||
| Operating Income | -84↑5.6% | -89↓8.8% | -82↑33.4% | -123↓77.1% | -70 | |
| Depreciation & Amortization | 5↑51.3% | 3↑54.7% | 2↑171.8% | 0.71↑9.6% | 0.65 | |
| EBITDA | -80↓22.0% | -66↑18.4% | -80↑34.6% | -123↓77.8% | -69 | |
| EBIT | -84↓23.2% | -68↑16.7% | -82↑33.4% | -123↓77.1% | -70 | |
| Interest & Other Income | ||||||
| Net Interest Income | 4↓48.7% | 7↑6.2% | 7↑139.9% | 3↑11917.4% | 0.02 | |
| Interest Income | 4↓48.7% | 7↑6.2% | 7↑139.9% | 3↑11917.4% | 0.02 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -21 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 6↓37.9% | 10↑18.5% | 8↑204.1% | 3↑144.2% | -6 | |
| Income Before Tax | -78↑1.6% | -79↓7.7% | -74↑38.9% | -121↓58.9% | -76 | |
| Income Tax Expense | 1↑164.0% | -2 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -80↓3.0% | -77↓4.8% | -74↑38.9% | -121↓58.9% | -76 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -80↓3.0% | -77↓4.8% | -74↑38.9% | -121↓58.9% | -76 | |
| Bottom-Line Net Income | -80↓3.0% | -77↓4.8% | -74↑38.9% | -121↓58.9% | -76 | |
| EPS (Basic) | -1.28↑3.0% | -1.32↑28.6% | -1.85↑48.2% | -3.57↓41.1% | -2.53 | |
| EPS (Diluted) | -1.28↑3.0% | -1.32↑28.6% | -1.85↑48.2% | -3.57↓41.1% | -2.53 | |
| Weighted Average Shares | 62↑6.3% | 58↑46.5% | 40↑20.8% | 33↑2.5% | 32 | |
| Weighted Average Diluted Shares | 62↑6.3% | 58↑46.5% | 40↑20.8% | 33↑2.5% | 32 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.